Immunotherapy

Roswell Park made national headlines last April in securing an agreement to bring Cuba’s encouraging lung cancer vaccine, CIMAvax, to the United States for clinical testing. Nearly one year later, Cuba is back in the news and CIMAvax is receiving renewed attention. One of the most frequently asked questions about this vaccine is, “When will it be available for lung cancer patients in the U.S.?”

In 2015 alone, more than 21,000 women will receive a diagnosis of ovarian cancer and approximately 14,000 women will die of the disease. Often diagnosed at advanced stages, ovarian cancer is aggressive and particularly tough to treat.

Amid a historic normalizing of relations between the United States and Cuba, a potentially game-changing step was recently taken in the field of lung cancer research.
As Immunotherapy Awareness Month winds down, we want to highlight three different clinical trials being led by physicians at our Division of Translational Immuno-Oncology of novel immunotherapy approaches for treating genitourinary cancers.